

Filed On Behalf Of:
Novartis Pharmaceuticals Corporation

By:
Nicholas N. Kallas
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BRECKENRIDGE PHARMACEUTICAL, INC, AND WEST-WARD
PHARMACEUTICALS INTERNATIONAL LIMITED

Petitioners,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owner.

IPR2017-01592¹
Patent No. 8,410,131

**PATENT OWNER'S SECOND UPDATED MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8(a)(3)**

¹ IPR2018-00507 has been joined to this proceeding (Paper 29, Apr. 03, 2018)

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(3), Novartis Pharmaceuticals Corporation (“Novartis” or “Patent Owner”) submits the following update to its March 19, 2018 Mandatory Notices (Paper 27).

REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)

The real party-in-interest information has not changed.

RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)

U.S. Patent No. 8,410,131 (“the ’131 Patent”) has been or is at issue in the following judicial proceedings: (1) Novartis Pharms. Corp. et al. v. West-Ward Pharms. Int’l Ltd., No. 15-474-RGA (D. Del.) (final judgment that claims 1-3 of the ’131 Patent were not proven invalid by reason of obviousness entered on December 21, 2017); (2) Novartis Pharms. Corp. et al. v. West-Ward Pharms. Int’l Ltd., No. 18-1434 (Fed. Cir.) (appeal from No. 15-474-RGA (D. Del.) by West-Ward Pharms. Int’l Ltd.); (3) Novartis Pharms. Corp. et al. v. Breckenridge Pharm., Inc., No. 16-431-RGA (D. Del.); (4) Novartis Pharms. Corp. et al. v. Breckenridge Pharm., Inc., No. 17-420-RGA (D. Del.); and (5) Novartis Pharms. Corp. et al. v. Teva Pharms. USA, Inc., No. 17-393-RGA (D. Del.) (stipulation of dismissal entered on February 26, 2018).

The ’131 Patent is also the subject of the following Petition for *Inter Partes* Review: West-Ward Pharms. Int’l Ltd. v. Novartis Pharms. Corp., *Inter Partes*

Review No. 2018-00507 (P.T.A.B.) (motion for joinder to *Inter Partes* Review No. 2017-01592 granted on April 3, 2018 (IPR2017-01592, Paper 29)).

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

The lead counsel information has not changed.

Patent Owner Novartis hereby notifies the Board that it is adding Christina Schwarz (admitted *pro hac vice*) and Jared Stringham (admitted *pro hac vice*) as back-up counsel. All other counsel information remains the same.

Additional back-up counsel:

Christina Schwarz
FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100
cschwarz@fchs.com

Jared L. Stringham
FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100
jstringham@fchs.com

SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)

The service information has not changed.

Respectfully submitted,

Dated: July 24, 2018

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

CERTIFICATE OF SERVICE

I certify that a copy of PATENT OWNER'S SECOND UPDATED MANDATORY NOTICES UNDER 37 C.F.R. § 42.8(a)(3) was served on July 24, 2018 by causing it to be sent by email to counsel for Petitioners at the following email addresses:

Daniel R. Evans (devans@merchantgould.com)

Jeffrey D. Blake (jblake @merchantgould.com)

Melissa M. Hayworth (mhayworth@merchantgould.com)

Keith A. Zullo (kzullo@goodwinprocter.com)

Marta E. Delsignore (mdelsignore@goodwinprocter.com)

Dated: July 24, 2018

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100